Abstract 5828: Effect of Roscovitine and mifepristone in luminal breast cancer cells

The cyclin dependent kinase (CDK)4/6 inhibitors have been recently approved in combination with endocrine therapy for luminal breast cancer treatment. On the other hand, the use of CDK2 inhibitors, such as Roscovitine, appears as a therapeutic alternative to overcome the acquisition of resistance to CDK4/6 inhibitors. However, there are few clinical trials using CDK2 inhibitors for breast cancer treatment. Most of the reports on the effects of...